Supernus Pharmaceuticals Current Ratio 2011-2018 | SUPN

Supernus Pharmaceuticals current ratio from 2011 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Supernus Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-09-30 $0.39B $0.14B 2.82
2018-06-30 $0.29B $0.10B 2.74
2018-03-31 $0.58B $0.12B 4.90
2017-12-31 $0.23B $0.12B 1.86
2017-09-30 $0.19B $0.11B 1.82
2017-06-30 $0.17B $0.09B 1.94
2017-03-31 $0.15B $0.08B 1.83
2016-12-31 $0.15B $0.08B 1.88
2016-09-30 $0.14B $0.07B 1.93
2016-06-30 $0.11B $0.07B 1.69
2016-03-31 $0.09B $0.06B 1.69
2015-12-31 $0.11B $0.06B 1.86
2015-09-30 $0.10B $0.04B 2.35
2015-06-30 $0.11B $0.04B 2.89
2015-03-31 $0.10B $0.03B 3.69
2014-12-31 $0.11B $0.03B 3.87
2014-09-30 $0.10B $0.02B 4.65
2014-06-30 $0.07B $0.02B 3.75
2014-03-31 $0.08B $0.03B 2.95
2013-12-31 $0.10B $0.03B 3.68
2013-09-30 $0.10B $0.03B 4.10
2013-06-30 $0.11B $0.02B 6.90
2013-03-31 $0.08B $0.03B 2.83
2012-12-31 $0.09B $0.02B 3.98
2012-09-30 $0.06B $0.03B 2.56
2012-06-30 $0.08B $0.02B 3.56
2012-03-31 $0.04B $0.02B 1.93
2011-12-31 $0.05B $0.02B 2.63
2011-09-30 $0.00B $0.00B 0.00
2011-06-30 $0.00B $0.00B 0.00
2011-03-31 $0.00B $0.00B 0.00
2010-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.043B $0.302B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $46.906B 8.33
Teva Pharmaceutical Industries (TEVA) Israel $18.283B 6.31
Mylan (MYL) United Kingdom $16.418B 6.76
Bausch Health Cos (BHC) Canada $8.901B 6.44
Dr Reddy's Laboratories (RDY) India $5.974B 23.83
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.817B 3.03
Amphastar Pharmaceuticals (AMPH) United States $1.124B 121.90
Homology Medicines (FIXX) United States $0.916B 0.00
CymaBay Therapeutics (CBAY) United States $0.591B 0.00
Assembly Biosciences (ASMB) United States $0.583B 0.00
Akorn (AKRX) United States $0.557B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.414B 0.00
Voyager Therapeutics (VYGR) United States $0.349B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.288B 0.00
Sol-Gel Technologies (SLGL) Israel $0.127B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.092B 0.00
Teligent (TLGT) United States $0.087B 0.00
Acasti Pharma (ACST) Canada $0.071B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.063B 0.00
Evoke Pharma (EVOK) United States $0.053B 0.00
Agile Therapeutics (AGRX) United States $0.037B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.017B 0.00
Aevi Genomic Medicine (GNMX) United States $0.015B 0.00